gilead has created a second pro-drug form of the active drug, tenofovir diphosphate, called tenofovir alafenamide. it differs from tenofovir disoproxil due to its activation in the lymphoid cells. this allows the active metabolites to accumulate in those cells, leading to lower systemic exposure and potential toxicities.